Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A3Adenosine Receptor Antagonists: Influence of the Chain at the N8Pyrazole Nitrogen
- 21 November 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (25) , 4768-4780
- https://doi.org/10.1021/jm001047y
Abstract
An enlarged series of pyrazolotriazolopyrimidines previously reported, in preliminary form (Baraldi et al. J. Med. Chem. 1999, 42, 4473−4478), as highly potent and selective human A3 adenosine receptor antagonists is described. The synthesized compounds showed A3 adenosine receptor affinity in the sub-nanomolar range and high levels of selectivity evaluated in radioligand binding assays at human A1, A2A, A2B, and A3 adenosine receptors. In particular, the effect of the chain at the N8 pyrazole nitrogen was analyzed. This study allowed us to identify the derivative with the methyl group at the N8 pyrazole combined with the 4-methoxyphenylcarbamoyl moiety at the N5 position as the compound with the best binding profile in terms of both affinity and selectivity (hA3 = 0.2 nM, hA1/hA3 = 5485, hA2A/hA3 = 6950, hA2B/hA3 = 1305). All the compounds proved to be full antagonists in a specific functional model where the inhibition of cAMP generation by IB-MECA was measured in membranes of CHO cells stably transfected with the human A3 receptor. The new compounds are among the most potent and selective A3 antagonists so far described. The derivatives with higher affinity at human A3 adenosine receptors proved to be antagonists, in the cAMP assay, capable of inhibiting the effect of IB-MECA with IC50 values in the nanomolar range, with a trend strictly similar to that observed in the binding assay. Also a molecular modeling study was carried out, with the aim to identify possible pharmacophore maps. In fact, a sterically controlled structure−activity relationship was found for the N8 pyrazole substituted derivatives, showing a correlation between the calculated molecular volume of pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives and their experimental Ki values.This publication has 21 references indexed in Scilit:
- Chiral Resolution and Stereospecificity of 6-Phenyl-4-phenylethynyl- 1,4-dihydropyridines as Selective A3 Adenosine Receptor AntagonistsJournal of Medicinal Chemistry, 1999
- [3H]‐SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranesBritish Journal of Pharmacology, 1998
- Binding of the radioligand [3H]‐SCH 58261, a new non‐xanthine A2A adenosine receptor antagonist, to rat striatal membranesBritish Journal of Pharmacology, 1996
- Synthesis and Biological Activities of Flavonoid Derivatives as A3 Adenosine Receptor AntagonistsJournal of Medicinal Chemistry, 1996
- A role for mast cells in adenosine A3 receptor‐mediated hypotension in the ratBritish Journal of Pharmacology, 1995
- Synthesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c] pyrimidine and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c] pyrimidine displaying potent and selective activity as A2a adenosine receptor antagonists.Bioorganic & Medicinal Chemistry Letters, 1994
- Cloned adenosine A3 receptors: Pharmacological properties, species differences and receptor functionsTrends in Pharmacological Sciences, 1994
- Molecular cloning and characterization of the human A3 adenosine receptor.Proceedings of the National Academy of Sciences, 1993
- Molecular cloning of a novel putative G‐protein coupled receptor expressed during rat spermiogenesisFEBS Letters, 1991
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976